ml210

JKE-1674 is an orally active glutathione peroxidase 4 (GPX4) inhibitor and the active metabolite of ML-210, which is converted to butyronitrile oxide JKE-1777. JKE-1674 kills LOX-IMVI cells in the same manner as ML-210 and is completely rescued by ferroptosis inhibitors.

ML-210 (CID 49766530) is a glutathione peroxidase 4 (GPX4) inhibitor (EC50=30 nM) that is covalent and selective. ML-210 has antitumor activity and induces ferroptosis.

Hydroxyl-ML-210 serves as a ligand for target proteins in PROTAC applications (Ligands for Target Protein for PROTACs). It is utilized in synthesis processes.

BML-210 (CAY10433) is a new-type HDAC inhibitor.